Metal and structure tuned in vitro antitumor activity of benzimidazole-based copper and zinc complexes

Four new complexes, Cu₂(p-2-bmb)₂Cl₄ (1), Cu₂(p-2-bmb)₂Br₄ (2), Zn₂(p-3-bmb)₂Cl₄ (3), and [Cu₃(p-3-bmb)₂Cl₄·(CH₃OH)₂] _n (4), have been synthesized under solvothermal reactions based on V-shaped flexible ligands 1-((2-(pyridin-2-yl)-1H-benzoimidazol-1-yl)methyl)-1Hbenzotriazole (p-2-bmb) and 1-((2-(pyridin-3-yl)-1H-benzoimidazol-1-yl)methyl)-1Hbenzotriazole (p-3-bmb). Complexes 1–3 are binuclear, whereas 4 is an infinite chain with trimetallic units, and then these complexes are further extended into 3D supramolecular architectures by π…π interactions and hydrogen bonds. In vitro antitumor activities of these complexes on four human tumor cell lines (gastric tumor cell line, esophagus tumor cell line, liver tumor cell line, colon tumor cell line) were evaluated by MTT assay. The results exhibit that these complexes inhibit the growth of cancer cells by inducing apoptosis, and the inhibition effect shows time- and dose-effect relationship.     

Dinuclear Schiff-base copper(II) complexes with various bridging groups

Three new centrosymmetric dinuclear copper(II) complexes, [Cu₂Cl₂(L¹)₂] (1), [Cu₂(μ _1,3-NCS)₂(L²)₂] (2), and [Cu₂(μ _1,1-N₃)₂(L³)₂] (3), where L¹, L², and L³ are the deprotonated forms of the Schiff bases 1-[(2-propylaminoethylimino)methyl]naphthalen-2-ol (HL¹), 1-[(3-methylaminopropylimino)methyl]naphthalen-2-ol (HL²), and 2-[(2-isopropylaminoethylimino)methyl]phenol (HL³), respectively, have been prepared and characterized by elemental analysis, IR spectra, and single-crystal X-ray crystallography. Each Cu is coordinated by the three donors of the Schiff bases and by two bridging groups, forming a square-pyramidal geometry.     

New benzimidazole derivatives: Design,synthesis, docking,and biological evaluation

The aim of this study was to synthesize novel enaminonitrile derivatives starting from 2-aminobenzimidazole and utilize this derivative for the preparation of novel heterocyclic compounds and assess their function for biological activity screening. The key precursor N-(1H-benzo[d]imidazol-2-yl)carbonohydrazonoyl dicyanide (2) was prepared in pyridine by coupling of diazotized 2-aminobenzimidazole (1) with malononitrile. Compound 2 was subjected to react with various secondary amines such as piperidine, morpholine, piperazine, diphenylamine, N-methylglucamine, and diethanolamine in boiling ethanol to give the acrylonitriles (2Z)-2-((1H-benzo[d]imidazol-2-yl)diazenyl)-3-amino-3-(piperidin-1-yl)acrylonitrile (3), (2Z)-2-((1H-benzo[d]imidazol-2-yl)diazenyl)-3-amino-3-morpholinoacrylonitrile (4), (2Z)-2-((1H-benzo[d]imidazol-2-yl)diazenyl)-3-amino-3-(piperazin-1-yl)acrylonitrile (5), (2Z)-2-((1H-benzo[d]imidazol-2-yl)diazenyl)-3-amino-3-(diphenylamino)acrylonitrile (6), (2Z)-2-((1H-benzo[d]imidazol-2-yl)diazenyl)-3-amino-3-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)acrylonitrile (7), and (2Z)-2-((1H-benzo[d]imidazol-2-yl)diazenyl)-3-amino-3-(bis(2-hydroxyethyl)amino)acrylonitrile (8), respectively. It has been found that the behaviour of nitrile derivative 2 towards hydrazine hydrate to the creation of 4-((1H-benzo[d]imidazol-2-yl)diazenyl)-1H-pyrazole-3,5-diamine (9). The reaction of malononitrile with compound 2 in an ethanolic solution catalyzed with sodium ethoxide afforded 4-amino-1-(1H-benzo[d]imidazol-2-yl)-6-imino-1,6-dihydropyridazine-3,5-dicarbonitrile (11). Moreover, malononitrile reacted with 7 in a boiling ethanolic sodium ethoxide solution to give 2-(5-((1H-benzo[d]imidazol-2-yl)diazenyl)-4-amino-6-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)pyrimidin-2-yl)acetonitrile (14). Heating 7 in boiling acetic anhydride and pyridine afforded (2R,3R,4R,5S)-6-(((1E)-2-((1-acetyl-1H-benzo[d]imidazol-2-yl)diazenyl)-1-(N-acetylacetamido)-2-cyanovinyl)(methyl)amino)hexane-1,2,3,4,5-pentayl pentaacetate (15). When compound 15 is heated for a long time in refluxing DMF including a catalytic of TEA, cyclization occurs to give the corresponding (2R,3R,4R,5S)-6-((1-acetyl-3-((1-acetyl-1H-benzo[d]imidazol-2-yl)diazenyl)-4-amino-6-oxo-1,6-dihydropyridin-2-yl)(methyl)amino)hexane-1,2,3,4,5-pentayl pentaacetate (16). In addition, triethyl orthoformate was reacted with compound 7 in the presence of acetic anhydride to afford the corresponding ethoxymethyleneamino derivative (2R,3R,4R,5S)-6-(((1E)-2-((1-acetyl-1H-benzo[d]imidazol-2-yl)diazenyl)-2-cyano-1-(((E) ethoxymethylene)amino)vinyl)(methyl)amino)hexane-1,2,3,4,5-pentayl pentaacetate (17). Also, it has been found that heating a mixture of 7 with DMF/DMA in anhydrous xylene yielded compound (1E)-N'-((1E)-2-((1H-benzo[d]imidazol-2-yl)diazenyl)-2-cyano-1-(methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)vinyl)-N,N-dimethylformimidamide (18). In addition, compound 7, when reacted with several acid anhydrides, allowed the matching phthalimide derivatives 19–26. The results showed that compound 14 has significantly higher ABTS and antitumor activities than the other compounds. Molecular modelling was also studied for compounds 22 and 24. The viability of four many cell lines—the African green monkey kidney epithelial cells (VERO), human breast adenocarcinoma cell line (MCF-7), human lung fibroblast cell line (WI-38), and human hepatocellular liver carcinoma cell line (HepG2) was examined to determine the antitumor activities of the newly synthesized compounds. Also, it was found that compounds 9, 11, 15, 16, 22, 23, 24 and 25 are strong against HepG2 cell lines, while 16, 22, and 25 are strong against WI-38 cell lines. Moreover, it was also found that compounds 16 and 22 are strong against VERO cell lines. On the other hand, compounds 7, 14, 15, 16, and 22 are strong while the rest of the other compounds are moderate against the MCF-7 cell line. The result of docking showed that compound 24 got stabilized inside the pocket with a very promising binding score of ? 8.12 through hydrogen bonds with Arg184 and Lys179, respectively.     

Anion-driven Ag(I) coordination architectures: structural diversity and photoluminescence behaviors

To observe anion impact on structural diversity of coordination architectures, three 1-D Ag(I) complexes with distinct features have been prepared, {[Ag(bpbib)₂(NO₃)]·C₃NH₉O)}_n (1), [Ag₂(bpbib)₂·(BF₄)₂]_n (2), and [Ag₂(bpbib)₂·(ClO₄)₂]_n (3), by the reactions of 4,4′-bis((2-(pyridin-2-yl)-¹H-benzo[d]imidazol-1-yl)methyl)biphenyl (bpbib) with Ag(I) salts. Complex 1 is a 1-D helical chain, whereas 2 and 3 bear ligand-unsupported Ag(I)···Ag(I) interaction-directed 1-D structural motif, with synergetic working of flexible organic linker and anions. All complexes exhibit strong triplet state emission at cryogenic temperatures, which profits from the reduction of nonradiative transitions.     

Unexpected complexation of allylpseudothiohydantoin hydrochlorides towards CuX (X = Cl,NO3, ClO4, BF4, 1/2SiF6). The first known examples of joint CuI(Cl,ClO4) and CuI(Cl,BF4) π-complexes

By means of alternating current-electrochemical synthesis starting from a mixture of 2-imino-3-(prop-2-en-1-yl)-1,3-thiazolidin-4-one (3-allylpseudothiohydantoin, napt) and 2-allylamino-1,3-thiazol-4(5H)-one (allylaminopseudothiohydantoin, aapt) hydrochlorides and corresponding copper(II) salts five new π-complexes, [Cu(napt)Cl] (1), [Cu₂(aapt)₂Cl]NO₃ (2), [Cu₂(aapt)₂Cl]BF₄ (3), [Cu₂(aapt)₂Cl]ClO₄ (4) and [Cu₂(aapt)₂Cl]₂SiF₆·2H₂O (5), were obtained and studied by X-ray single crystal diffraction and IR-spectroscopy. Napt and aapt molecules are selectively coordinated to Cu⁺ depending on the anion type. In crystals of 1 and 5, the organic ligands are attached to the metal in a chelating N,(C=C)-bidentate mode. The aapt molecule in 2-4 acts as a tridentate chelating ligand, being coordinated to the copper(I) ion through the heterocyclic N atom, carbonyl O atom, and C=C bond of allyl group, forming an original cationic [Cu₂(aapt)₂Cl]⁺ fragment with both a bridging Cl^– ion and O atom of the C=O group. In the presence of the doubly charged SiF₆^2– anion, Cu(I) in 5 prefers to be bonded with two bridging Cl^– ions, rather than the C=O group, causing [Cu₂(aapt)₂Cl]⁺ units to associate into the infinite cationic chains. Crystals of 3 and 4 are the first known examples of the simultaneous BF₄^–/Cl^– or ClO₄^–/Cl^– participation in copper(I) π-complex formation.     

Synthesis,structures, catalytic,and anticancer activities of some coordination compounds involving two new triazole derivatives

Five N-heterocyclic carboxylate-based coordination complexes, [Co(L¹)₂(H₂O)₂]·2H₂O (1), [Cd(L¹)₂(H₂O)₂]·2H₂O (2), [Co(L²)(H₂O)₃] (3), [Ni(L²)(H₂O)₃] (4), and [Cu₂(L²)₂(H₂O)₂] (5), have been synthesized and characterized by elemental analysis, IR spectroscopy, Powder X-ray diffraction, thermogravimetric analyses, and single-crystal X-ray crystallography, where HL¹ is 2-((5-amino-1H-1,2,4-triazol-3-yl)thio)acetic acid and H₂L² is 2-((5-amino-1-(carboxymethyl)-1H-1,2,4-triazol-3-yl)thio)acetic acid. In these complexes, the hydrogen bonds (H-bonds) play an important role in their packing structures. Complex 1 has nine H-bonds showing a 3-D sqc38 topology. Complex 2 has 17 H-bonds exhibiting a 3-D hxl network. Complexes 3 and 4 are isomorphic, both of which possess ten H-bonds to present a 3-D btc topology. Complex 5 with eight H-bonds forms a 2-D sq1 structure. In addition, complex 3 catalyzes the decolorization of methyl orange. Meanwhile, 1, 3, and 5 show certain anticancer activities to inhibit the growth of HepG2 cells.     

Tuning the bridging modes of Cu-azido complexes with Schiff bases by varying the terminal groups

Three azido-bridged copper(II) complexes, [Cu₂(L¹)₂(μ_1,1,3-N₃)₂] _n ·2nH₂O (1), [Cu₄(L²)₄(μ_1,1-N₃)₂(μ_1,1,3-N₃)₂] _n (2), and [Cu₂(L³)₂(μ_1,1-N₃)₂] (3), where L¹, L², and L³ are the deprotonated forms of 4-bromo-2-[(2-methylaminoethylimino)methyl]phenol (HL¹), 4-bromo-2-[(2-ethylaminoethylimino)methyl]phenol (HL²), and 4-bromo-2-[(2-isopropylaminoethylimino)methyl]phenol (HL³), respectively, have been prepared and structurally characterized by single-crystal X-ray diffraction analysis and IR spectra. The slight differences in the terminal groups of the Schiff bases lead to different bridging modes of the azido groups.     

Vinyl-addition polymerization of norbornene catalyzed by (pyrazol-1-ylmethyl)pyridine divalent iron, cobalt and nickel complexes

Complexes of 2-((3,5-dimethyl)-1H-pyrazol-1-ylmethyl)pyridine (L1), 2-((3,5-ditert-butyl-1H-pyrazol-1-yl)methyl)pyridine (L2), 2-((3,5-diphenyl)-1H-pyrazol-1-yl)methyl)pyridine (L3), 2-((3,5-bis(trifluoromethyl)-1H-pyrazol-1-ylmethyl)pyridine (L4) and 2,6-bis(3,5-dimethyl-1H-pyrazol-1-yl)methyl)pyridine (L5) with cobalt(II), iron(II) and nickel(II), Ni(L1)Cl₂ (1), Co(L1)Cl₂ (2), Fe(L1)Cl₂ (3), Ni(L2)Cl₂ (4), Ni(L3)Cl₂ (5), Co(L3)Cl₂ (6), Fe(L3)Cl₂ (7), Ni(L4)Cl₂ (8) and Ni(L5)Cl₂ (9), were used as catalyst precursors to produce vinyl-addition type norbornene polymers. Both the identity of the metal center and nature of ligand affected the polymerization behaviour of the resultant catalysts. Nickel catalysts were generally more active than the corresponding iron and cobalt analogues. The polynorbornene produced have high molecular weights (0.5-2.1 × 10⁶ g/mol) and narrow molecular weight distributions. Analyses of polymer microstructure using NMR and IR spectroscopy confirmed the polymers produced to be vinyl-addition polynorbornene.     

Synthesis,characterization, and antitumor activity of mononuclear and dinuclear ruthenium complexes

Abstract

Dinuclear ruthenium complexes [Ru₂(bpy)₄BL](ClO₄)₂ (Ru-1), where bpy = 2,2′-bipyridine and BL = 2,2′-((1E,1′E)-((E)-diazene-1,2-diyl-bis(2,1-phenylene))-bis(azanylylidene))bis(methanylylidene))diphenol (a bidentate bridging ligand), and mononuclear ruthenium complexes [Ru(bpy)₂L](ClO₄) (Ru-2), where L = (E)-2-((phenylimino)methyl)phenol, were synthesized and characterized by elemental analysis and electrospray ionization mass spectrometry. Their photophysical and electrochemical properties were also studied. The cytotoxicity of the two complexes in vitro was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The results indicated that Ru-1 and Ru-2 exhibited significant dose-dependent cytotoxicity to human breast cancer (MCF-7), gastric cancer (SGC-7901), cervical cancer (Hela), and lung cancer (A549) tumor cell lines. Ru-1 showed excellent antitumor effects in a cellular study (IC₅₀ values of 3.61 μM for MCF-7 human breast cancer cells in vitro). However, Ru-2 exhibited the highest cytotoxicity to Hela cells; the IC₅₀ value is 3.71 μM. The results reveal that Ru-1 and Ru-2 have obvious selectivity and might be a potential anticancer agent that could improve the efficacy of common anticancer therapies.     

Four-coordinate N-heterocyclic carbene (NHC) copper(I) complexes with brightly luminescence properties

Three four-coordinate N-heterocyclic carbene (NHC) copper(I) complexes, [Cu(Py-Im)(POP)](PF₆) (P1), [Cu(Py-BenIm)(POP)](PF₆) (P2), and [Cu(Py-c-BenIm)(POP)](PF₆) (P3) (Py-Im = 3-methyl-1-(pyridin-2-yl)-1H-imidazolylidene, Py-BenIm = 3-methyl-1-(pyridin-2-yl)-1H-benzo[d]imidazolylidene, Py-c-BenIm = 3-methyl-1-(pyridin-2-ylmethyl)-1H-benzo[d]imidazolylidene, POP = bis([2-diphenylphosphino]-phenyl)ether), have been synthesized without transmetalation of the NHC–Ag(I) complex for the first time. The photophysical properties of the resultant NHC–Cu(I) complexes have been systematically investigated via spectroscopic methods. All complexes exhibit good photoluminescence properties with long excited-state lifetimes and moderate quantum yields. Density functional theory and time dependent density functional theory calculations were employed to rationalize the photophysical properties of the NHC–Cu(I) complexes.     

An x-ray diffraction study of the reaction products of copper(II) chloride with N<Superscript>1</Superscript>,N<Superscript>2</Superscript>-bis(5-methylpyridin-2-yl)oxalamide

Polymeric complexes of [Cu₂Cl₂L₂]_∞ copper(I) chloride (1) (L = N¹,N²-bis(5-methylpyridin-2-yl)-oxalamide)) and {[Cu₂(C₂O₄)Cl₂L](L)·2H₂O}_∞ copper(II) chloride (2) are obtained. The complexes are studied by powder and single crystal XRD. It is found that during the reaction of L with copper(II) chloride in the formation of complex 1 copper(II) is reduced to copper(I), while the formation of complex 2 is accompanied by the hydrolysis of the ligand.     

吡唑衍生物的铜和银配合物的合成、结构及光谱研究

在有机溶剂中,我们设计合成了4种配合物:[Cu2Cl4pz*2](1),[Cu2Cl4(L2)2](2),[CuCl(L2)2H2O]Cl.H2O(3),[Ag(L3)2]NO3(4)(pz*=3,5-二甲基吡唑;L2=二吡唑甲烷;L3=4-碘-3,5-二甲基吡唑)。通过元素分析、红外光谱、紫外光谱、X-ray粉末和X-ray单晶衍射方法对其结构进行了表征,分析了其光谱及结构特征。结构分析表明,吡唑烷均采取二齿配位模式,配合物1、3和4中金属的配位数分别为五、六和二;配合物2中则存在2种不同配位模式的中心铜离子。并用Gaussian03量子化学程序包,采用密度泛函理论(DFT)中的B3LYP方法,研究了3个铜配合物的稳定性和电荷分布。     

Metallacycle-based complexes based on a flexible pyridyl–benzimidazole derivative

Three new coordination complexes, {Cd(pbmb)(NO₃)₂} _n (1), {Ag(pbmb)(NO₃)(C₃H₆O)} _n (2), and {Hg₂(pbmb)₂Cl₄} _n (3), have been synthesized under solvothermal or solution reactions based on a flexible N-heterocyclic ligand 1-((2-(pyridin-4-yl)-1H-benzoimidazol-1-yl)methyl)-1H-benzotriazole (pbmb) and structurally characterized by single-crystal X-ray diffraction, IR spectrum, and elemental analyses. Both 1 and 2 display a 1-D chain structure with metallacycle unit while 3 shows a binuclear cycle motif. The aromatic rings are directing groups for π?···?π stacking interactions. The π?···?π interactions and hydrogen bonds extend the simple chain structure and binuclear structure to 3-D supramolecular architectures. Complexes 1 and 3 exhibit strong luminescence in the solid state at room temperature whereas 2 shows fluorescence quenching.     

Synthesis and physiochemical studies on binuclear Cu(II) complexes derived from 2,6-[(N-phenylpiperazin-1-yl)methyl]-4-substituted phenols

Preparation of the ligands HL¹ = 2,6-[(N-phenylpiperazin-1-yl)methyl]-p-ethylphenol; HL² = 2,6-[(N-phenylpiperazin-1-yl)methyl]-p-methoxyphenol and HL³ = 2,6-[(N-phenylpiperazin-1-yl)methyl]-p-nitrophenol are described together with their Cu(II) complexes with different bridging units. The exogenous bridges incorporated into the complexes are: hydroxo [Cu₂L(OH)(H₂O)₂](ClO₄)₂.H₂O (L¹=1a, L² =1b, L³ =1c), acetato [Cu₂L(OAc)₂]ClO₄.H₂O (L¹ =2a, L² =2b, L³ =2c) and nitrito [Cu₂L¹(NO₂)₂(H₂O)₂]ClO₄.H₂O (L¹=3a, L² =3b, L³ =3c). Complexes1a,1b,1c and2a,2b,2c contain bridging exogenous groups, while3a,3b,3c possess only open μ-phenolate structures. Both the ligands and complexes were characterized by spectral studies. Cyclic voltammetric investigation of these complexes revealed that the reaction process involves two successive quasireversible one-electron steps at different potentials. The first reduction potential is sensitive to electronic effects of the substituents at the aromatic ring of the ligand system, shifting to positive potentials when the substituents are replaced by more electrophilic groups. EPR studies indicate very weak interaction between the two copper atoms. Various covalency parameters have been calculated.     

Coordination of di- and triimine ligands at ruthenium(II) and ruthenium(III) centers: structural,electrochemical and radical scavenging studies

Herein, we explore the coordination of di- and triimine chelators at ruthenium(II) and ruthenium(III) centers. The reactions of 2,6-bis-((4-tetrahydropyranimino)methyl)pyridine (thppy), N¹,N²-bis((3-chromone)methylene)benzene-1,2-diamine (chb), and tris-((1H-pyrrol-2-ylmethylene)ethane)amine (H₃pym) with trans-[Ru^IICl₂(PPh₃)₃] afforded the diamagnetic ruthenium(II) complex cis-[RuCl₂(thppy)(PPh₃)] (1) and the paramagnetic complexes [mer-Ru₂(μ-chb)Cl₆(PPh₃)₂] (2), and [Ru(pym)] (3), respectively. The complexes were characterized by IR, NMR, and UV–vis spectroscopy and molar conductivity measurements. The structures were confirmed by single crystal X-ray diffraction studies. The redox properties of the metal complexes were probed via cyclic- and squarewave voltammetry. Finally, the radical scavenging capabilities of the metal complexes towards the NO and 2,2-di(4-tert-octylphenyl)-1-picrylhydrazyl (DPPH) radicals were investigated     

Syntheses,structures, and properties of copper and cadmium complexes with quinoline-based benzimidazole

A new tridentate ligand 2-((quinolin-8-yloxy)methyl)benzimidazole (L) and three coordination compounds, [CuLCl₂] (1), [CuL(H₂O)(SO₄)?· 2H₂O] _n (2), and {[Cd₂L₂Cl₄][CdLCl₂(H₂O)]₂}?·?H₂O (3), have been synthesized and characterized. Single crystal structure analyses reveal extensive intermolecular hydrogen bonding, resulting in generation of 1-D–3-D supramolecular networks. Compounds 1 and 2 constitute the first examples of Cu complexes containing both 8-hydroxyquinoline and benzimidazole, while 3 represents the first Cd complex bearing this ligand. Complexes 1–3 show similar quasi-reversible electrochemical behaviors. Complex 2 exhibits a predominantly ferromagnetic interaction between copper centers, and 3 has good fluorescence and can be used as an optical material.     

Assembly of 1-D and decanuclear cage compounds from copper halide,cyclohexenephosphonic acid,and 3-(2-pyridyl)pyrazole

The reactions of cyclohexenephosphonic acid (C₆H₉PO₃H₂) and 3-(2-pyridyl)pyrazole (2-pyPzH) with copper(II) chloride and copper(II) bromide affords a 1-D compound [Cu(2-pyPz)Cl] (1) and a decanuclear [Cu₁₀(OH)₄(C₆H₉PO₃)₆(2-pyPz)₄] (2) cage complex. In 1, adjacent copper ions are bridged by two 2-pyPz ligands into dimers, which are further linked by Cl^? into a ladder-like chain. Compound 2 has a decanuclear cage structure, the overall cage can be viewed as composed of two Cu₄(OH)₂(2-pyPz)₂ wings that are bridged by a central Cu₂P₂O₆ rim. Variable-temperature magnetic susceptibility studies indicate that both compounds show antiferromagnetic interactions between copper centers.     

Synthesis,structure, and magnetic properties of two dimer paddle-wheel CuII toluate complexes with nitronyl nitroxide radicals

Two new paddle-wheel dimeric copper complexes, [Cu₂(4-MePhCOO)₄(NITmPy)₂] (1) and [Cu₂(3-MePhCOO)₄(NITmPy)₂] (2) (NITmPy?=?2-(3-pyridyl)-4,4,5,5-tetramethyl-4,5-dihydro1H-imidazolyl-1-oxyl-3-oxide), were synthesized by reaction of copper toluate and NITmPy. Single crystal X-ray analyses revealed that both complexes are symmetrical dimers. Cu with four deprotonated methyl-benzoate bridging ligands form a paddle-wheel core and pyridyl nitrogen of radical ligands at the apical position. Based on the Cu–Cu axis of 1 and 2, we exploited the steric constraints of the methyl groups and induced the paddle-wheel. Two magnetic exchange pathways with strong antiferromagnetic interaction between dimeric Cu^II ions and weak antiferromagnetic interaction between NITmPy ligands exist in the complexes. IR and powder X-ray diffraction of the complexes were also studied.     

Manganese(II) complexes of hydrazone based NNO-donor ligands and their catalytic activity in the oxidation of olefins

The reaction between tridentate NNO donor hydrazone ligands, (E)-2-cyano-N′-(phenyl(pyridin-2-yl)methylene)acetohydrazide (HL¹) and (E)-2-cyano-N′-(1-(pyridin-2-yl)ethylidene)acetohydrazide (HL²), with MnCl₂·4H₂O in methanol resulted in [Mn(HL¹)Cl₂(CH₃OH)] (1) and [Mn(HL²)Cl₂(CH₃OH)] (2). Molecular structures of the complexes were determined by single-crystal X-ray diffraction. All of the investigated compounds were further characterized by elemental analysis, FT-IR, TGA, and UV–Vis spectroscopy. These complexes were used as catalysts for olefin oxidation in the presence of tert-butylhydroperoxide (TBHP) as an oxidant. Under similar experimental conditions with equal manganese loading, the presence of [Mn(HL²)Cl₂(CH₃OH)] (2) resulted in higher conversion than [Mn(HL¹)Cl₂(CH₃OH)] (1).     

Reaction of Dimethyl Sulfoxide with 4-Acyloxycoumarins

Dimethyl sulfoxide converts 4-acetoxycoumarin (1) exclusively to 2-(2-hydroxybenzoyl)-2-[(methylthio)methyl]-2,3-dihydro-4 H-furo[3,2-c]chromen-4-one (3) at 180°C under a nitrogen atmosphere, but in the absence of nitrogen, the products obtained are dicoumarol and its dehydrative cyclization products 7 H-bis[1]benzopyrano[4,3-b: 3′,4′-c]pyran-6,8-dione (9) and (3). Under similar conditions, 4-benzoyloxycoumarin (1a) affords benzoic acid, 4-hydroxy-3-({2-[(methylthio)methyl]-3-oxo-2,3-dihydro-1-benzofuran-2-yl}methyl)-2H-chromen-2-one (7), and 3-(2-hydroxybenzoyl)-3,4-dihydro-2H,5H-pyrano[2,3-b] chromen-5-one (8).